Department of Radiotherapy;
Jiangxi Provincial Tumour Hospital;
Nanchang 330029;
Jiangxi Province;
China;
Department of Radiotherapy;
The Affiliated Cancer Hospital of Nanchang University;
Nanchang 330029;
Jiangxi Province;
China;
Faculty of Medicine;
Burning Rock Biotech;
Guangzhou 510300;
Guangdong Province;
China;
Programmed death-ligand 1; Tumor mutational burden; Bladder cancer; Camrelizumab; Next-generation sequencing; Case report;